Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis.
Title | Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Tsiami, A. P., Goulis D. G., Sotiriadis A. I., & Kolibianakis E. M. |
Journal | Hormones (Athens) |
Volume | 20 |
Issue | 3 |
Pagination | 449-461 |
Date Published | 2021 Sep |
ISSN | 2520-8721 |
Keywords | Clomiphene, Female, Fertility Agents, Female, Humans, Infertility, Female, Letrozole, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy |
Abstract | BACKGROUND: Polycystic ovary syndrome (PCOS) is a common cause of anovulatory infertility. According to the latest guidelines, letrozole should be considered as the first-line pharmacological treatment for women with WHO Group II anovulation or PCOS. However, the use of letrozole as an ovulation induction agent is not FDA or EMA approved, and its use is "off-label." The main concern with respect to letrozole regards its potential teratogenic effect on the fetus. |
DOI | 10.1007/s42000-021-00289-z |
Alternate Journal | Hormones (Athens) |
PubMed ID | 34033068 |